SignaBlok awarded NCI / NIH SBIR Phase I grant to test first-in-class TREM-1 inhibitor in combination with chemotherapy for treatment of pancreatic cancer

SignaBlok > News > SignaBlok awarded NCI / NIH SBIR Phase I grant to test first-in-class TREM-1 inhibitor in combination with chemotherapy for treatment of pancreatic cancer

SignaBlok > News > SignaBlok awarded NCI / NIH SBIR Phase I grant to test first-in-class TREM-1 inhibitor in combination with chemotherapy for treatment of pancreatic cancer

SignaBlok awarded NCI / NIH SBIR Phase I grant to test first-in-class TREM-1 inhibitor in combination with chemotherapy for treatment of pancreatic cancer

Vera

View posts by Vera